secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001933414-24-000044
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys completes enrollment of 261 subjects in pivotal Advance-HTN trial; topline Q1 2025
--------------------------------------------------------------------------------

- Target enrollment of 261 subjects achieved in Phase 2 Advance-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
- Topline data expected Q1 2025; additional subjects in screening may enroll over next several weeks.
- Trial is randomized, double-blind, placebo-controlled, add-on to standardized antihypertensive regimen.
- Virtual KOL event scheduled for October 30, 2024 to discuss unmet need and clinical program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/0001933414-24-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/mlys-20240925.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer